Aclarion, Inc. ACON

What this company does

The Company is addressing the chronic low back pain market by initially focusing on improving the outcomes of surgical interventions to treat chronic discogenic low back pain, with the technology intended to assist surgeons in determining the optimal surgical procedure for a patient undergoing surgery for pain isolated to their lumbar spine. Aclarion has developed proprietary signal processing software that transforms spectroscopy data into clear biomarkers, which are exclusively licensed from the Regents of University of California, San Francisco ("UCSF"), and are the key data inputs for Aclarion's proprietary algorithms that, when applied, determine if an intervertebral disc is consistent with pain. As of December 31, 2025, Aclarion's patent portfolio includes 28 U.S. Patents, 24 Foreign Patents, 7 pending U.S. patent applications, and 12 pending Foreign patent applications, including patents and patent applications exclusively licensed from the Regents of the University of California. Aclarion has developed a software application called NOCISCAN, which uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The NIH included Aclarion's technology as one of the technologies selected to participate in its $150 million Back Pain Consortium (BACPAC) Research Program, a translational, patient-centered effort to address the need for effective and personalized therapies for chronic low back pain.

Written from the business description in Aclarion, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 18 March 2026. Every sentence was checked against that document before publication.